{"filings":[{"id":2115076,"accession_number":"0001872789-26-000029","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2026-08-07T11:07:45+00:00","items":["2.02","9.01"],"status":"ready","headline":"Embecta Q3 FY26 revenue down 8.1% to $271.7M; adjusted EPS $0.56 vs $1.12","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported revenue $271.7M, down 8.1% YoY; US down 24.6%, International up 11.5%.","GAAP net income $21.1M ($0.36 diluted EPS) vs $45.5M ($0.78) in prior year.","Adjusted EPS $0.56 vs $1.12; adjusted operating margin 25.5% vs 36.9%.","Owen Mumford acquisition closed mid-quarter, contributed $13.8M revenue; integration progressing.","FY26 guidance raised: adj. operating margin 23.5-24.0% (prior 22.25-23.25%); adj. EPS $1.80-$1.90 (prior $1.55-$1.75)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1996196,"accession_number":"0001872789-26-000026","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K/A","filed_at":"2026-07-31T20:35:15+00:00","items":["9.01"],"status":"ready","headline":"Embecta files Owen Mumford FY2025 audited financials; revenue £68.6M, net profit £1.68M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Owen Mumford FY2025 (Sep 30) revenue £68.6M, gross profit £33.1M, operating loss £825K.","Net profit for the year £1.68M; total comprehensive income £1.32M after FX losses.","Net assets £102.7M; cash and equivalents £29.6M.","Auditor issued qualified opinion due to omission of comparative period; financials under UK GAAP.","Acquisition closed May 15, 2026; pro forma financials also filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":453796,"accession_number":"0000947871-26-000546","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2026-05-15T13:15:29+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Embecta completes acquisition of Owen Mumford for £100M upfront plus up to £50M earnout","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition completed May 15, 2026; Owen Mumford is a UK-based medical device and drug-delivery technology manufacturer.","Upfront cash payment of £100M at closing; up to £50M additional based on Aidaptus auto-injector sales through June 2029.","Strategic move to transform embecta into a broad-based medical supplies company serving obesity, diabetes, autoimmune, and anaphylaxis markets.","Adds differentiated drug-delivery platform with Aidaptus next-generation auto-injector and strong IP portfolio.","Combines Owen Mumford's device design, molding, and assembly with embecta's global commercial infrastructure and manufacturing scale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96458,"accession_number":"0001872789-26-000014","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Embecta Q2 revenue drops 14.4%; FY2026 guidance cut sharply; dividend slashed to $0.01","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $221.8M, -14.4% YoY; US -29.4%, Intl +2.1%; pen needles -17.8%.","Adjusted EPS $0.27 vs $0.70 YoY; GAAP diluted EPS -$0.07.","FY2026 revenue guidance lowered to $1,015-1,035M; adj. EPS to $1.55-1.75.","Board authorized $100M repurchase plan; quarterly dividend cut from $0.15 to $0.01, payable June 15.","Owen Mumford acquisition on track for May 2026; adds ~$30M revenue, dilutive ~$0.15 to FY adj. EPS."],"consensus_eps_estimate":null,"consensus_eps_actual":0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":483000000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110359,"accession_number":"0000947871-26-000310","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Embecta to acquire Owen Mumford for up to £150M; adds drug-delivery platform","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash payment of £100M at closing; up to £50M earnout based on Aidaptus net sales by end of 2028.","Owen Mumford generated £69.4M revenue in FY2025; transaction expected to close in Embecta's fiscal Q3 2026.","Deal unanimously approved by Embecta board; expected to be accretive to adjusted net income after FY2028.","Acquisition positions Embecta in drug-delivery devices for chronic care (obesity, diabetes, autoimmune, anaphylaxis).","Embecta plans to fund upfront with borrowings under its revolving credit facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110358,"accession_number":"0000947871-26-000153","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Embecta's annual meeting votes approve all proposals including director elections and auditor ratification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 7 board nominees elected; Christopher R. Reidy received 45.8M for vs 2.7M against.","Ratification of Ernst & Young as FY2026 auditor passed: 53.1M for, 55K against.","Advisory say-on-pay approved: 47.7M for, 787K against.","Amendment to 2022 Equity-Based Compensation Plan approved: 41.4M for, 7.0M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110357,"accession_number":"0001872789-26-000005","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Embecta Q1 FY2026 revenue $261.2M, net income $44.1M, EPS $0.74; maintains guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported revenues $261.2M, down 0.3% YoY; adjusted constant currency revenue declined 2.0%.","Net income $44.1M ($0.74 diluted EPS); adjusted net income $42.3M ($0.71 adjusted EPS).","U.S. revenue fell 7.6%; international revenue rose 8.4% (4.6% adjusted constant currency).","Paid down $37.5M of term loan B debt; declared $0.15 quarterly dividend payable Mar 17, 2026.","FY2026 guidance reaffirmed: reported revenues $1.071B-$1.093B, adjusted EPS $2.80-$3.00."],"consensus_eps_estimate":null,"consensus_eps_actual":0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":261200000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126954,"accession_number":"0001872789-25-000033","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Embecta Q4 rev down 7.7% to $264M, net income $26.4M; FY2026 adj EPS guide $2.80-3.00","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 FY2025 revenue $264.0M (-7.7% YoY); GAAP net income $26.4M ($0.45 diluted EPS), up from $14.6M.","Full year FY2025 revenue $1,080.4M (-3.8% YoY); GAAP net income $95.4M ($1.62 diluted EPS); adjusted EPS $2.95.","Reduced debt by ~$184.5M in FY2025, exceeding $110M target; free cash flow $182M for FY2025.","Board declared quarterly dividend of $0.15 per share, payable Dec 18, 2025 to holders of record Dec 5.","FY2026 guidance: reported revenue $1,071-1,093M; adjusted EPS $2.80-3.00; adjusted operating margin 29-30%."],"consensus_eps_estimate":null,"consensus_eps_actual":1.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":1080400000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126953,"accession_number":"0000947871-25-001028","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Embecta board members Albritton resigns immediately, Melcher to retire at 2026 meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David A. Albritton resigned effective Nov 17, 2025, for personal reasons; no disagreement with company.","LTG (Ret.) David F. Melcher will not stand for re-election at 2026 annual meeting, retiring from board.","Board size reduced from nine to eight after Albritton's resignation.","Dev Kurdikar (CEO) expected to become Chairman; Dr. Claire Pomeroy expected as Lead Independent Director.","Both departing directors served since Board inception in April 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143754,"accession_number":"0001872789-25-000025","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Embecta Q3 revenue up 8.4% to $295.5M; raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Adjusted EPS $1.12 vs $0.74 prior year; reported EPS $0.78.","US revenue +11.6%; international +5.0% (reported).","FY2025 guidance raised: adj. EPS now $2.90-$2.95; adj. EBITDA margin 37.25%-37.50%.","Declared $0.15 quarterly dividend payable Sep 15, 2025 to holders of record Aug 29.","Paid down ~$52.4M of term loan B in Q3; YTD debt reduction ~$112M meets annual target."],"consensus_eps_estimate":null,"consensus_eps_actual":1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":816400000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161985,"accession_number":"0001872789-25-000016","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Embecta reaffirms FY2025 guidance, unveils long-range plan with flat revenue growth, $600M FCF target","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reaffirmed FY2025 guidance: revenue $1.073-1.090B, adjusted EPS $2.70-$2.90, adjusted gross margin 62.75%-63.75%.","Long-range plan (2025-2028): flattish constant currency revenue CAGR, adjusted operating margin ~28%-30%.","Targets ~$600M cumulative free cash flow over LRP; plans to repay $450M-$500M of debt.","Strategic priorities: strengthen core insulin injection business, expand product portfolio, increase financial flexibility through cost savings and debt reduction.","Inaugural Analyst and Investor Day held May 22, 2025, with webcast and presentation materials available online."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161984,"accession_number":"0001872789-25-000009","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Embecta Q2 revenue down 9.8% to $259M; adjusted EPS $0.70 vs $0.67; lowers FY25 revenue growth guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $259M, down 9.8% reported and 7.7% adjusted constant currency; U.S. -8.4%, International -7.0%.","Adjusted EPS $0.70 vs $0.67; adjusted operating margin 31.4% vs 26.1%.","FY25 adjusted constant currency revenue growth guidance lowered to (4.0%)-(2.5%) from (2.5%)-(1.0%); adjusted EPS reaffirmed $2.70-$2.90.","Declared quarterly dividend $0.15/share, payable June 13, 2025 to holders of record May 28, 2025.","Paid down ~$27.4M of term loan B debt during the quarter; cash and equivalents $212.3M."],"consensus_eps_estimate":0.7905,"consensus_eps_actual":0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":520900000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180046,"accession_number":"0000947871-25-000163","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Embecta stockholders elect three directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class III nominees Hombach, Kurdikar, Melcher elected with >98% of votes cast.","Ernst & Young ratified as independent auditor for fiscal 2025 with 99.8% support.","Advisory say-on-pay resolution approved with ~97.2% of votes cast in favor.","Annual meeting held February 12, 2025; all proposals passed as recommended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180045,"accession_number":"0001872789-25-000003","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Embecta Q1 revenue down 5.6% to $261.9M; net income nil; adj. EPS $0.65","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $261.9M (-5.6% reported, -4.8% constant currency); U.S. down 4.6%, international down 5.1% constant currency.","Net income nil; adjusted diluted EPS $0.65 vs $0.61 prior year.","Adjusted operating margin 30.7% vs 27.9% prior year; FY2025 guidance raised to 29.5%-30.5% from 29%-30%.","Quarterly dividend $0.15 per share, payable March 14, 2025 to holders of record Feb 28, 2025.","Paid $32.4M of term loan B (SOFR+300bps); restructuring of patch pump program on track for H1 FY2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":261900000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196842,"accession_number":"0000947871-24-000973","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Embecta appoints Anthony Roth as VP, Chief Accounting Officer; Elguicze steps down","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anthony Roth appointed VP, Chief Accounting Officer and principal accounting officer, effective Dec 2, 2024.","Base salary $400,000; target bonus 40% of salary; annual LTI target $325,000; one-time RSU grant of $325,000 vesting over 3 years.","Jake Elguicze steps down as principal accounting officer but continues as CFO and principal financial officer.","Roth previously served as CAO at Ascential's Digital Commerce and Summit Health."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196841,"accession_number":"0001872789-24-000031","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"Embecta Q4 beats; discontinues patch pump; restructuring saves $60-65M annually; FY2025 EPS guidance $2.70-2.90","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 reported rev $286.1M (+1.5%), GAAP EPS $0.25, adjusted EPS $0.45.","FY2024 rev $1,123.1M (+0.2%), adjusted EPS $2.45, GAAP EPS $1.34.","Discontinues insulin patch pump; expects $35-45M pre-tax charges in FY2025; annualized savings $60-65M.","FY2025 guidance: rev $1,093-1,110M, adjusted EPS $2.70-2.90, adj. EBITDA margin 35.5-36.5%.","Board declares $0.15/share dividend payable Dec 18, 2024 to holders of record Dec 6, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":1123100000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213137,"accession_number":"0000947871-24-000673","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Embecta CAO Brian Capone resigns; CFO Jake Elguicze assumes interim PAO role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brian Capone resigned as Chief Accounting Officer and principal accounting officer effective Aug 12, 2024, for another opportunity.","Departure is not due to any disagreement with Embecta on financial statements, controls, or policies.","CFO Jake Elguicze will serve as interim principal accounting officer in addition to his CFO role, effective Aug 12, until a successor is named.","Elguicze will not receive additional compensation for the interim PAO duties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213136,"accession_number":"0001872789-24-000026","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Embecta Q3 revenues down 4.8%; adjusted EPS up, guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenues $272.5M, down 4.8% YoY; U.S. down 6.7%, international down 2.5% reported.","Adjusted net income $43.0M ($0.74 diluted) vs $39.8M ($0.69) YoY; adj. EBITDA margin 36.4%.","Raised FY2024 outlook: adjusted EPS now $2.30-$2.35 (prev $2.20-$2.30), adj. gross margin 65.25%-65.50%.","Board declared $0.15 quarterly dividend, payable Sept 13, 2024 to holders of record Aug 27.","Progress on FDA 510(k) for open-loop patch pump; ~93% of global revenue now on own systems."],"consensus_eps_estimate":null,"consensus_eps_actual":1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":837000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232245,"accession_number":"0001872789-24-000016","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Embecta Q2 revenue up 3.6% to $287.2M; raises FY2024 guidance above prior range","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $287.2M (+3.6% reported, +4.5% constant currency); U.S. +0.8%, International +6.8%.","Adjusted EPS of $0.67 vs $0.75 prior year; adjusted operating margin of 26.1% vs 30.6%.","Raised FY2024 guidance: revenue $1,111-1,116M (prev. $1,094-1,116M), adj. EPS $2.20-2.30 (prev. $1.95-2.15).","FDA continues review of insulin patch pump 510(k); ERP implementation covers ~85% of revenue.","Declared quarterly dividend of $0.15/share, payable June 14, 2024 to holders of record May 28, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":564500000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250518,"accession_number":"0001872789-24-000010","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Embecta extends transition and logistics services from BD through Nov 1, 2024 for LATAM/China markets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Limited extension of certain ERP services under TSA and LSA until Nov 1, 2024 for LATAM, China, Hong Kong, Macau, Taiwan.","TSA service charges increase to 125% of prior rate during extension period.","LSA administrative fee set at 1.25% of New Revenue; factoring/servicing fees at 125% of pre-2024 levels.","Both amendments executed March 28, 2024, with cost mark-ups for continued interim support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250517,"accession_number":"0001872789-24-000003","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2024-02-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Embecta Q1 revenue $277.3M, adj EPS $0.61; raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $277.3M (+0.6% reported; -0.3% constant currency); U.S. revenue down 0.5%, international up 1.8%.","GAAP net income $20.1M ($0.35 diluted EPS) vs. $35.2M ($0.61) prior year; adjusted EPS $0.61 vs. $0.96 prior.","Raised FY2024 guidance: revenue $1,094-$1,116M (from $1,085-$1,105M); adj EPS $1.95-$2.15 (from $1.90-$2.10).","Dividend of $0.15/share declared, payable March 15, 2024 to holders of record Feb 28, 2024.","Filed 510(k) for open-loop patch pump with FDA; transitioned ~60% of revenue to own ERP system."],"consensus_eps_estimate":null,"consensus_eps_actual":0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":277300000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250516,"accession_number":"0000947871-24-000101","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2024-02-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Embecta shareholders elect three directors, ratify auditor, approve say-on-pay and equity plan amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Dr. Milton Morris, Dr. Claire Pomeroy, Karen Prange as Class II directors with >45.9M votes each.","Ratified Ernst & Young as independent auditor for fiscal 2024: 51.6M for, 96.7K against.","Advisory say-on-pay approved: 46.0M for, 586K against, 5.1M broker non-votes.","Equity-based compensation plan amendment approved: 42.5M for, 4.1M against, 5.1M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268076,"accession_number":"0001872789-23-000029","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2023-11-21T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Embecta Q4 revenue $281.9M (+2.7%); guides FY2024 revenue down 1-3%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP EPS $0.10, adjusted EPS $0.59; full-year adjusted EPS $2.99.","FY2024 revenue guidance $1,085-1,105M (reported -3% to -1%); adj. EPS $1.90-$2.10.","Dividend declared $0.15/share, payable Dec 15, 2023, record Dec 4.","Added as exclusive/dual-preferred brand with three top Medicare Part D payers starting Jan 2024.","Type 2 closed loop insulin pump development on track with FDA Breakthrough Device Designation."],"consensus_eps_estimate":null,"consensus_eps_actual":1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":1120800000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285306,"accession_number":"0001872789-23-000024","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Embecta Q3 revenue $286.1M (-1.7%); raises FY2023 adj. EPS guidance to $2.75-$2.80","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 adjusted EPS $0.69 vs. $1.07 prior year; net income $15.2M, down from $62.4M.","U.S. revenue $153.9M (-2.6%); international revenue $132.2M (-0.7% reported, +2.4% constant currency).","FY2023 adj. EPS guidance raised to $2.75-$2.80 from $2.50-$2.60; revenue range narrowed to $1,107-$1,113M.","Adjusted EBITDA margin guidance raised to ~33.5% from ~32.5%; adjusted gross margin ~66.0%.","Board declared $0.15 quarterly dividend, payable Sept 13, 2023, record Aug 25."],"consensus_eps_estimate":null,"consensus_eps_actual":1.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":838900000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285305,"accession_number":"0000947871-23-000814","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Embecta amends bylaws to update director nomination and proxy solicitation procedures","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board amended bylaws effective August 2, 2023, revising director nomination and proxy solicitation requirements.","Amendments include compliance with SEC Rule 14a-19 (universal proxy) and related notification procedures.","Additional ministerial, clarifying, and conforming changes made to the bylaws.","Full text of amended bylaws and marked version filed as Exhibits 3.1 and 3.2.","No financial impact or change in fiscal year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285304,"accession_number":"0001872789-23-000021","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2023-07-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Embecta CHRO Ajay Kumar resigns effective July 16; receives $720K severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ajay Kumar stepped down as Chief Human Resources Officer, effective July 16, 2023, per mutual agreement.","Severance includes $720,000 cash (12 months base salary plus target STI), prorated 2023 bonus, and 12 months of COBRA premiums.","Unvested equity awards that would vest on or before Nov 30, 2023 will continue to vest; outplacement services provided for 12 months.","Separation Agreement dated June 30, 2023, contingent on release of claims after termination date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":305159,"accession_number":"0001872789-23-000011","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Embecta beats Q2 with $277M revenue (+4% CC); raises FY2023 adj EPS guidance to $2.50-$2.60","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $277.1M, +4.0% constant currency; US +3.6%, international +4.4% constant currency.","Adjusted EPS $0.75, adjusted operating margin 30.6%, adjusted EBITDA margin 34.9%.","FY2023 guidance raised: revenue $1,101-1,113M (prev $1,084-1,107M), constant currency growth 0-1%.","Adjusted EPS guidance raised to $2.50-2.60 from $2.20-2.35; adj gross margin ~64.5%, adj op margin ~28%.","Declared $0.15/share quarterly dividend; advancing insulin patch pump via Tidepool collaboration for type 2 closed-loop."],"consensus_eps_estimate":null,"consensus_eps_actual":0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":552800000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324642,"accession_number":"0001872789-23-000003","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2023-02-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Embecta Q1 FY2023 adj. EPS $0.96 beats; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $275.7M, down 4.7% reported, up 0.7% constant currency.","GAAP EPS $0.61; adjusted EPS $0.96; adjusted op. margin 36.9%.","Raises FY2023 guidance: revenue $1,084-$1,107M, adj. EPS $2.20-$2.35.","U.S. revenue -1.1%, International -8.7% reported, +2.6% constant currency.","Declares $0.15/share dividend, payable March 13, 2023 to holders of record Feb 27."],"consensus_eps_estimate":null,"consensus_eps_actual":0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":275700000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324641,"accession_number":"0000947871-23-000158","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2023-02-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Embecta shareholders elect directors, approve auditor and executive compensation at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All three Class I director nominees elected, with Christopher Reidy receiving 42M for, 8.3M against.","Ratification of Ernst & Young as independent auditor for FY2023 approved with 53.6M for, 415k against.","Advisory vote on named executive officer compensation approved with 49.0M for, 1.8M against.","Advisory vote on frequency of say-on-pay set to annual with 50.0M votes for 1-year option."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342483,"accession_number":"0001872789-22-000019","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2022-12-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Embecta reports Q4 FY2022 net loss $17.2M; FY2023 guidance revenue $1,050-$1,073M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $274.6M, down 8.7% reported; net loss $17.2M vs income $97.1M prior year, includes $58.9M impairment.","FY2022 revenue $1,129.5M, down 3.1%; net income $223.6M vs $414.8M; adjusted EBITDA margin 40.7% vs 48.5%.","Quarterly dividend $0.15/share declared, payable Jan 11, 2023 to holders of record Dec 30, 2022.","Preliminary FY2023 guidance: revenue $1,050-$1,073M (down 5-7% reported); adj. diluted EPS $1.75-$2.00.","Entered co-promotion agreement with Intuity Medical for POGO Automatic blood glucose monitor in U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359186,"accession_number":"0000947871-22-001036","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2022-09-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Embecta sets first annual meeting for Feb 9, 2023; proxy deadlines announced","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting of stockholders scheduled for February 9, 2023.","Deadline for Rule 14a-8 stockholder proposals: October 7, 2022.","Deadline for proxy access director nominations: October 7, 2022.","Deadline for other proposals (including non-proxy-access director nominations): November 11, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359185,"accession_number":"0001872789-22-000013","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Embecta Q3 revenue $291.1M, net income $62.4M; raises H2 FY2022 margin guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $291.1M (-1.3% reported, +2.0% constant currency); US +4.1%, international -7.1%.","Net income $62.4M ($1.07 diluted EPS) vs $104.7M prior year; adjusted EBITDA margin 40.5% vs 48.7%.","Declared $0.15/share quarterly dividend, payable Sept. 14 to holders of record Aug. 26.","Raised H2 FY2022 adjusted gross margin guidance to mid-60%s (from low-60%s) and adjusted EBITDA margin to mid-30%s (from low-30%s); maintained revenue ~$555M.","Developing type 2 closed-loop insulin patch pump with FDA Breakthrough Device Designation."],"consensus_eps_estimate":null,"consensus_eps_actual":4.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":854900000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377992,"accession_number":"0001872789-22-000007","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2022-05-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Embecta Q2 revenue $274.5M (-3.4% reported); guides H2 FY22 revenue ~$555M (-7% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $274.5M, down 3.4% reported (-1.3% constant currency); US -5.8%, international +3.6% constant currency.","Net income $79.6M ($1.38 diluted EPS) vs $107.9M ($1.87) in prior-year quarter.","Adjusted EBITDA margin 42.6% vs 49.8% as supply chain disruptions and inflation pressured results.","H2 FY22 guidance: revenue ~$555M (-7% reported / -3.5% constant currency); non-GAAP gross margin low-60%s; adj. EBITDA margin low-30%s."],"consensus_eps_estimate":null,"consensus_eps_actual":3.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":563800000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377991,"accession_number":"0001193125-22-097622","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2022-04-06T23:59:59+00:00","items":["1.01","2.03","5.02","5.03","5.05","8.01","9.01"],"status":"ready","headline":"Embecta completes spin-off from BD, lists on NASDAQ as EMBC with $1.65B in new debt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Spin-off effective April 1, 2022; shares distributed to BD stockholders; EMBC listed on Nasdaq.","Embecta is the largest diabetes injection device producer, making ~8B devices/yr for ~30M patients across 100+ countries.","Entered $500M revolver, $950M term loan B, and $200M 6.75% senior secured notes due 2030 to fund separation and operations.","Appointed Devdatt Kurdikar as CEO, Jacob Elguicze as CFO, and other executive officers; board expanded to nine directors.","Estimates insulin delivery market at $6-8B annually; manufacturing footprint of ~800K sq ft in US, Ireland, and China."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396324,"accession_number":"0001193125-22-083889","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2022-03-24T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Embecta expands board, approves stock split and share increase for BD spin-off","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appointed Robert J. Hombach to board, increasing size from 3 to 4; Hombach also joins Audit Committee.","Filed charter amendment to increase authorized common shares and effect a stock split, effective March 22, 2022.","Actions taken in connection with the spin-off of Embecta from BD, with distribution to BD shareholders on March 22."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396323,"accession_number":"0001193125-22-082093","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2022-03-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Embecta discloses spin-off pro forma: $1.65B debt, $1.44B distribution to BD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Spin-off of 100% Embecta shares to BD shareholders at 1:5 ratio; distribution date April 1, 2022.","Pro forma assumes ~$1.65B in aggregate debt and ~$1.44B distribution to BD, including $1.24B cash.","Pro forma financials reflect transaction adjustments for standalone capital structure and autonomous entity costs.","Selected unaudited pro forma financial info as of Sep 30, 2021, Dec 31, 2021, and LTM Dec 31, 2021 filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396322,"accession_number":"0001193125-22-067116","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2022-03-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Embecta holds investor day; presentation provides company mission but no financial targets disclosed in excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Embecta Corp. hosted an investor day on March 7, 2022 as announced by BD.","Exhibit 99.1 attached to 8-K contains only a mission/vision slide; no specific financial figures or guidance available.","Presentation materials also posted on BD's investor website for review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396321,"accession_number":"0001193125-22-066045","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2022-03-04T23:59:59+00:00","items":["5.04"],"status":"ready","headline":"Embecta 401(k) Plan enters blackout period March 31 to early April due to spin-off","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Blackout begins March 31, 2022, expected to end during week of April 3, 2022.","Blackout due to spin-off from BD, expected to close on April 1, 2022.","Participants cannot exchange, take loans, or get distributions from BD or Embecta Common Stock Funds during blackout."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396320,"accession_number":"0001193125-22-035814","cik":1872789,"company_name":"Embecta Corp.","ticker":"EMBC","form_type":"8-K","filed_at":"2022-02-11T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Embecta sets April 1 spin-off from BD; issues $500M senior secured notes due 2030","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BD to distribute 1 Embecta share for every 5 BD shares held on March 22, 2022; distribution expected April 1, 2022.","Embecta common stock to list on Nasdaq under symbol 'EMBC' after separation.","Embecta issued $500M of 5.000% senior secured notes due 2030, secured by assets post-spin.","Separation intended to be tax-free for BD shareholders (except cash in lieu of fractional shares).","Embecta will be independent pure-play diabetes care company; produces ~7.6B units of injection devices annually."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":195484686.37082067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}